{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:05:24Z","timestamp":1790802324627,"version":"4.1.0"},"reference-count":262,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jbo.2024.100635","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T15:25:56Z","timestamp":1727105156000},"page":"100635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence"],"prefix":"10.1016","volume":"48","author":[{"given":"Atefeh","family":"Barzegari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Kamyab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Aratikatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Nejati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Valizade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Eltouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jbo.2024.100635_b0005","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/bph.14999","article-title":"Bone sarcomas in the immunotherapy era","volume":"178","author":"Heymann","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbo.2024.100635_b0010","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221124696","article-title":"Current status and prospects of clinical treatment of osteosarcoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.spinee.2016.11.002","article-title":"Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine","volume":"17","author":"Arshi","year":"2017","journal-title":"Spine J"},{"key":"10.1016\/j.jbo.2024.100635_b0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/1471-2407-10-357","article-title":"The epidemiology of bone cancer in 0\u201339 year olds in northern England, 1981\u20132002","volume":"10","author":"Eyre","year":"2010","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.jbo.2024.100635_b0025","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.2106\/JBJS.RVW.24.00071","article-title":"The impact of social determinants of health on the prognosis of primary bone tumors: a systematic review","volume":"12","author":"Ebrahimi","year":"2024","journal-title":"JBJS Rev."},{"key":"10.1016\/j.jbo.2024.100635_b0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/BLO.0b013e318059b8c9","article-title":"Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: national cancer data base report","volume":"459","author":"Damron","year":"2007","journal-title":"Clin. Orthopaed. Rel. Res."},{"key":"10.1016\/j.jbo.2024.100635_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707211","article-title":"A novel treatment for Ewing\u2019s sarcoma: chimeric antigen receptor-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MOP.0b013e32832b1111","article-title":"Bone tumors: osteosarcoma and Ewing's sarcoma","volume":"21","author":"Heare","year":"2009","journal-title":"Curr. Opin. Pediatr."},{"issue":"9","key":"10.1016\/j.jbo.2024.100635_b0045","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s11999-008-0335-z","article-title":"Osteosarcoma development and stem cell differentiation","volume":"466","author":"Tang","year":"2008","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"10440","key":"10.1016\/j.jbo.2024.100635_b0050","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ctrv.2006.05.005","article-title":"Primary bone osteosarcoma in the pediatric age: state of the art","volume":"32","author":"Longhi","year":"2006","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2024.100635_b0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2015.00181","article-title":"Immunotherapy of childhood sarcomas","volume":"5","author":"Roberts","year":"2015","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b0065","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<745::AID-CNCR9>3.0.CO;2-D","article-title":"Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery","volume":"78","author":"Sheth","year":"1996","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b0070","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00264-010-1065-x","article-title":"Low-grade chondrosarcoma of bone: experiences from the Vienna Bone and Soft Tissue Tumour Registry","volume":"35","author":"Funovics","year":"2011","journal-title":"Int. Orthop."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1302\/0301-620X.84B1.0840093","article-title":"Risk factors for survival and local control in chondrosarcoma of bone","volume":"84","author":"Fiorenza","year":"2002","journal-title":"J. Bone Joint Surg. Br."},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0080","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3109\/17453674.2011.636668","article-title":"Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up","volume":"82","author":"Andreou","year":"2011","journal-title":"Acta Orthop."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(05)70023-1","article-title":"Cryosurgery in aggressive, benign, and low-grade malignant bone tumours","volume":"6","author":"Veth","year":"2005","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0090","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2214\/ajr.144.5.955","article-title":"Giant cell tumor of bone: highlights of 407 cases","volume":"144","author":"Dahlin","year":"1985","journal-title":"AJR Am. J. Roentgenol."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0095","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0360-3016(89)90160-0","article-title":"Radiation therapy in the treatment of difficult giant cell tumors","volume":"17","author":"Schwartz","year":"1989","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.6004\/jnccn.2017.0017","article-title":"NCCN guidelines insights: bone cancer, version 2.2017","volume":"15","author":"Biermann","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"27","key":"10.1016\/j.jbo.2024.100635_b0105","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: current treatment and a collaborative pathway to success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/ijms22020813","article-title":"Osteosarcoma pathogenesis leads the way to new target treatments","volume":"22","author":"Fernandes","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2024.100635_b0115","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","author":"Dobosz","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0120","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0135","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.drudis.2018.02.012","article-title":"Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts","volume":"23","author":"Zheng","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0140","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.jbo.2024.100635_b0145","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3892\/mco.2022.2567","article-title":"Advances and challenges of CAR T therapy and suitability of animal models (Review)","volume":"17","author":"Ramos-Cardona","year":"2022","journal-title":"Mol. Clin. Oncol."},{"issue":"10297","key":"10.1016\/j.jbo.2024.100635_b0160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0170","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin. Transl. Immunol."},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0175","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3390\/cancers13061229","article-title":"Metabolic and mitochondrial functioning in chimeric antigen receptor (CAR)\u2014T Cells","volume":"13","author":"Rad","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jbo.2024.100635_b0185","first-page":"1","article-title":"Angiogenic factors and cytokines in diabetic retinopathy","volume":"11","author":"Abcouwer","year":"2013","journal-title":"J. Clin. Cell. Immunol."},{"issue":"6382","key":"10.1016\/j.jbo.2024.100635_b0190","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CAR s and TRUCK s: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0200","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.cgt.7700710","article-title":"A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells","volume":"11","author":"Moeller","year":"2004","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jbo.2024.100635_b0205","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fonc.2019.00069","article-title":"Next generation CAR T cells for the immunotherapy of high-grade glioma","volume":"9","author":"Petersen","year":"2019","journal-title":"Front. Oncol."},{"issue":"18","key":"10.1016\/j.jbo.2024.100635_b0210","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.3390\/cancers13184704","article-title":"Chimeric antigen receptor T cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma","volume":"13","author":"Terry","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2022.2567","article-title":"Advances and challenges of CAR T therapy and suitability of animal models","volume":"17","author":"Ramos-Cardona","year":"2022","journal-title":"Molec. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b0220","doi-asserted-by":"crossref","first-page":"e0133152","DOI":"10.1371\/journal.pone.0133152","article-title":"IGF1R-and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0225","first-page":"802","article-title":"CD19-targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"14","author":"Davila","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol.: H&O"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0230","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/mt.2014.58","article-title":"The other face of chimeric antigen receptors","volume":"22","author":"Dotti","year":"2014","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0235","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc \u2018spacer\u2019domain in the extracellular moiety of chimeric antigen receptors avoids \u2018off-target\u2019activation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther."},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b0240","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jbo.2024.100635_b0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cytogfr.2017.06.009","article-title":"Improving homing in T cell therapy","volume":"36","author":"Vignali","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jbo.2024.100635_b0250","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.jbo.2024.100635_b0255","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2024.100635_b0260","article-title":"CAR T cell therapy in primary brain tumors: current investigations and the future","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0265","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1038\/s41467-023-39097-x","article-title":"ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma","volume":"14","author":"Mensali","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0270","doi-asserted-by":"crossref","first-page":"e28313","DOI":"10.1002\/pbc.28313","article-title":"VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma","volume":"67","author":"Englisch","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0275","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1186\/s12885-022-10229-8","article-title":"B7\u2013H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003633","article-title":"Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors","volume":"10","author":"Hu","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"620","key":"10.1016\/j.jbo.2024.100635_b0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0290","doi-asserted-by":"crossref","DOI":"10.1002\/cnr2.1394","article-title":"Surface expression of the immunotherapeutic target G(D2) in osteosarcoma depends on cell confluency","volume":"4","author":"Wiebel","year":"2021","journal-title":"Cancer Reports"},{"key":"10.1016\/j.jbo.2024.100635_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659662","article-title":"B7\u2013H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma","volume":"11","author":"Long","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbo.2024.100635_b0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J. ImmunoTherap. Cancer"},{"key":"10.1016\/j.jbo.2024.100635_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691741","article-title":"A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T Cells","volume":"12","author":"Talbot","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbo.2024.100635_b0310","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cancers13122857","article-title":"HLA-G and HLA-E immune checkpoints are widely expressed in Ewing sarcoma but have limited functional impact on the effector functions of antigen-specific CAR T cells","volume":"13","author":"Altvater","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b0315","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1158\/2159-8290.CD-20-0896","article-title":"A chimeric gm-csf\/il18 receptor to sustain car t-cell function","volume":"11","author":"Lange","year":"2021","journal-title":"Cancer Discov."},{"issue":"3\u20134","key":"10.1016\/j.jbo.2024.100635_b0320","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","article-title":"Chimeric antigen receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours","volume":"28","author":"Hsu","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0325","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-01012-y","article-title":"GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma","volume":"13","author":"Park","year":"2020","journal-title":"J Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0330","first-page":"674","article-title":"GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas","volume":"10","author":"Chulanetra","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0335","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2019.02.014","article-title":"EZH2 inhibition in ewing sarcoma upregulates G(D2) expression for targeting with gene-modified T cells","volume":"27","author":"Kailayangiri","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jbo.2024.100635_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100332","article-title":"Adoptive transfer of TILs plus anti-PD1 therapy: an alternative combination therapy for treating metastatic osteosarcoma","volume":"25","author":"Wang","year":"2020","journal-title":"J. Bone Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2024.100635_b0345","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7\u2013H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jbo.2024.100635_b0350","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/ijc.32743","article-title":"GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma","volume":"146","author":"Charan","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"19","key":"10.1016\/j.jbo.2024.100635_b0355","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells","volume":"23","author":"Fernandez","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.jbo.2024.100635_b0360","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b0365","doi-asserted-by":"crossref","first-page":"e0133152","DOI":"10.1371\/journal.pone.0133152","article-title":"IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0370","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/bjc.2013.356","article-title":"Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging","volume":"109","author":"Liebsch","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0375","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/bjc.2012.57","article-title":"The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting","volume":"106","author":"Kailayangiri","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031210","article-title":"Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection","volume":"7","author":"Lehner","year":"2012","journal-title":"Plos One"},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0385","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/cgt.2011.83","article-title":"Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma","volume":"19","author":"Rainusso","year":"2012","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0390","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/0008-5472.CAN-11-2778","article-title":"Genetically modified T cells targeting interleukin-11 receptor \u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases","volume":"72","author":"Huang","year":"2012","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.jbo.2024.100635_b0395","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.3390\/cancers13174469","article-title":"Chimeric antigen receptor T-cell therapy: the light of day for osteosarcoma","volume":"13","author":"Lin","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jbo.2024.100635_b0400","first-page":"1","article-title":"Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0405","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181fe7825","article-title":"PRISMA statement","volume":"22","author":"Moher","year":"2011","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0410","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Method."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12874-021-01295-w","article-title":"Quality assessment tools used in systematic reviews of in vitro studies: a systematic review","volume":"21","author":"Tran","year":"2021","journal-title":"BMC Med. Res. Method."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0420","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jvim.15852","article-title":"Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma","volume":"34","author":"Flesner","year":"2020","journal-title":"J. Vet. Int. Med."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0425","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1312239","article-title":"Ewing sarcoma partial regression without GvHD by chondromodulin-I\/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells","volume":"6","author":"Thiel","year":"2017","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0430","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1007\/s13277-015-4615-4","article-title":"V\u03b39V\u03b42 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma","volume":"37","author":"Sun","year":"2016","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0435","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1025194","article-title":"Effective combination treatment of GD2-expressing neuroblastoma and Ewing\u2019s sarcomausing anti-GD2 ch14.18\/CHO antibody with V\u03b39V\u03b42+\u03b3\u03b4T cells","volume":"5","author":"Fisher","year":"2016","journal-title":"OncoImmunology"},{"issue":"28","key":"10.1016\/j.jbo.2024.100635_b0440","doi-asserted-by":"crossref","first-page":"43267","DOI":"10.18632\/oncotarget.9218","article-title":"Human HLA-A*02:01\/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo","volume":"7","author":"Blaeschke","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0445","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1007\/s13277-014-1764-9","article-title":"Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1","volume":"35","author":"Krishnadas","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.jbo.2024.100635_b0450","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3389\/fimmu.2018.01239","article-title":"Decitabine enhances V\u03b39V\u03b42 T cell-mediated cytotoxic effects on osteosarcoma cells via the NKG2DL-NKG2D axis","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"issue":"39","key":"10.1016\/j.jbo.2024.100635_b0455","doi-asserted-by":"crossref","first-page":"66137","DOI":"10.18632\/oncotarget.19821","article-title":"Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children","volume":"8","author":"Merker","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0460","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/14653249.2010.515581","article-title":"Zoledronate-activated V\u03b39\u03b3\u03b4 T cell-based immunotherapy is feasible and restores the impairment of \u03b3\u03b4 T cells in patients with solid tumors","volume":"13","author":"Noguchi","year":"2011","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0465","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ijc.21817","article-title":"Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes","volume":"119","author":"Rodeberg","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071581","article-title":"MHC class I-restricted TCR-transgenic CD4(+)T cells against STEAP1 mediate local tumor control of Ewing sarcoma in vivo","volume":"9","author":"Schober","year":"2020","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.jbo.2024.100635_b0475","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/1078-0432.CCR-22-0721","article-title":"Membrane-anchored and tumor-targeted IL12 (attIL12)-PBMC therapy for osteosarcoma","volume":"28","author":"Yang","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0480","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001846","article-title":"133p53\u03b1 enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity","volume":"9","author":"Legscha","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"21","key":"10.1016\/j.jbo.2024.100635_b0485","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.18632\/oncotarget.2505","article-title":"Induction of a specific CD8+ T-cell response to cancer\/testis antigens by demethylating pre-treatment against osteosarcoma","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0490","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jor.21579","article-title":"Sensitization of human osteosarcoma cells to V\u03b39V\u03b42 T-cell-mediated cytotoxicity by zoledronate","volume":"30","author":"Li","year":"2012","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.jbo.2024.100635_b0495","article-title":"Targeting Ewing sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with anti-MCAM chimeric antigen receptor (CAR) modified Natural Killer (NK) cells","volume":"69","author":"Luo","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jbo.2024.100635_b0500","article-title":"Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0505","doi-asserted-by":"crossref","first-page":"e1273301","DOI":"10.1080\/2162402X.2016.1273301","article-title":"Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo","volume":"6","author":"Kirschner","year":"2017","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b0510","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3892\/or.2015.4161","article-title":"Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma","volume":"34","author":"Kawano","year":"2015","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0515","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3892\/ol.2016.4714","article-title":"In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma","volume":"12","author":"He","year":"2016","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0520","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3892\/ol.2016.4175","article-title":"Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma","volume":"11","author":"Kawano","year":"2016","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052926","article-title":"TNF-\u03b1 and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors","volume":"7","author":"Miwa","year":"2012","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0530","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3171\/2017.1.JNS162610","article-title":"A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab","volume":"128","author":"Fujii","year":"2018","journal-title":"J. Neurosurg."},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b0535","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002267","volume":"9","author":"Chu","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0540","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250050","article-title":"Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G","volume":"6","author":"Kailayangiri","year":"2017","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.jbo.2024.100635_b0545","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/pbc.25619","article-title":"Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells","volume":"62","author":"Jamitzky","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0550","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ymthe.2018.11.006","article-title":"A potent tumor-reactive p53-specific single-chain TCR without on- or off-target autoimmunity in vivo","volume":"27","author":"Echchannaoui","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jbo.2024.100635_b0555","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2051-1426-2-25","article-title":"Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells","volume":"2","author":"Beard","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0560","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","article-title":"T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing","volume":"74","author":"Kudo","year":"2014","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b0565","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jbo.2024.100635_b0570","first-page":"S14","article-title":"Clinical development of piggyBac transposon mediated-CAR-T cells for osteosarcoma","volume":"66","author":"Nakamura","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0575","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0580","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0585","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28313","article-title":"VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma","volume":"67","author":"Englisch","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"15","key":"10.1016\/j.jbo.2024.100635_b0590","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0595","first-page":"674","article-title":"GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas","volume":"10","author":"Chulanetra","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0600","doi-asserted-by":"crossref","first-page":"e1394","DOI":"10.1002\/cnr2.1394","article-title":"Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency","volume":"4","author":"Wiebel","year":"2021","journal-title":"Cancer Reports"},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b0605","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3390\/cancers13122857","article-title":"HLA-G and HLA-E immune checkpoints are widely expressed in Ewing sarcoma but have limited functional impact on the effector functions of antigen-specific CAR T cells","volume":"13","author":"Altvater","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0610","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2019.02.014","article-title":"EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells","volume":"27","author":"Kailayangiri","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01012-y","article-title":"GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma","volume":"13","author":"Park","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jbo.2024.100635_b0620","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","article-title":"NKG2D and its ligands in cancer","volume":"51","author":"Dhar","year":"2018","journal-title":"Curr. Opin. Immunol."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0625","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1034\/j.1399-0039.2003.00070.x","article-title":"NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer","volume":"61","author":"Cerwenka","year":"2003","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jbo.2024.100635_b0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.871076","article-title":"Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0635","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","article-title":"Effect of NKG2D ligand expression on host immune responses","volume":"235","author":"Champsaur","year":"2010","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0640","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2015.07.042","article-title":"Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D\u2013NKG2DL dependent manner","volume":"368","author":"Fern\u00e1ndez","year":"2015","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0645","doi-asserted-by":"crossref","first-page":"e31210","DOI":"10.1371\/journal.pone.0031210","article-title":"Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection","volume":"7","author":"Lehner","year":"2012","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.jbo.2024.100635_b0650","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells","volume":"23","author":"Fern\u00e1ndez","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0655","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/mt.2015.119","article-title":"T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice","volume":"23","author":"VanSeggelen","year":"2015","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b0660","first-page":"66","article-title":"B7\u2013H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Am. J. Clin. Exp. Immunol."},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b0665","doi-asserted-by":"crossref","first-page":"21785","DOI":"10.1002\/jcp.28936","article-title":"The novel non-immunological role and underlying mechanisms of B7\u2013H3 in tumorigenesis","volume":"234","author":"Zhou","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"14","key":"10.1016\/j.jbo.2024.100635_b0670","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7\u2013H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0675","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7\u2013H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbo.2024.100635_b0680","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659662","article-title":"B7\u2013H3 as a target for CAR-T cell therapy in skull base chordoma","volume":"11","author":"Long","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-022-10229-8","article-title":"B7\u2013H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2024.100635_b0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691741","article-title":"A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T cells","volume":"12","author":"Talbot","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0695","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1158\/0008-5472.CAN-08-4845","article-title":"The interleukin-11 receptor \u03b1 as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples","volume":"69","author":"Lewis","year":"2009","journal-title":"Cancer Res."},{"issue":"30","key":"10.1016\/j.jbo.2024.100635_b0700","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1073\/pnas.1704173114","article-title":"BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation","volume":"114","author":"Lewis","year":"2017","journal-title":"Proc. Nat. Acad. Sci."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0705","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b0710","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-03-0038","article-title":"Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing\u2019s sarcoma","volume":"10","author":"Fuchs","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jbo.2024.100635_b0715","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-12-3913","article-title":"Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice","volume":"73","author":"Chinnasamy","year":"2013","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.jbo.2024.100635_b0720","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jbo.2024.100635_b0725","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0065-2776(03)81006-4","article-title":"HLA-G molecules: from maternal-fetal tolerance to tissue acceptance","volume":"81","author":"Carosella","year":"2003","journal-title":"Adv. Immunol."},{"issue":"8","key":"10.1016\/j.jbo.2024.100635_b0730","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.4049\/jimmunol.166.8.5018","article-title":"HLA-G2,-G3, and-G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis","volume":"166","author":"Riteau","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbo.2024.100635_b0735","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.597468","article-title":"The role of HLA-G in tumor escape: manipulating the phenotype and function of immune cells","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2024.100635_b0740","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1073\/pnas.95.8.4510","article-title":"HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance","volume":"95","author":"Paul","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.jbo.2024.100635_b0745","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.168.9.4772","article-title":"A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape","volume":"168","author":"Wiendl","year":"2002","journal-title":"J. Immunol."},{"issue":"13","key":"10.1016\/j.jbo.2024.100635_b0750","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1158\/0008-5472.CAN-06-4588","article-title":"Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release","volume":"67","author":"Morandi","year":"2007","journal-title":"Cancer Res."},{"issue":"28","key":"10.1016\/j.jbo.2024.100635_b0755","doi-asserted-by":"crossref","first-page":"25783","DOI":"10.1074\/jbc.M011272200","article-title":"Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction","volume":"276","author":"van Kempen","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b0760","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1242\/jcs.02280","article-title":"Internalization and recycling of ALCAM\/CD166 detected by a fully human single-chain recombinant antibody","volume":"118","author":"Piazza","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jbo.2024.100635_b0765","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/126906","article-title":"Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor","volume":"2012","author":"Federman","year":"2012","journal-title":"Sarcoma"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0770","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/pros.10161","article-title":"ALCAM\/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions","volume":"54","author":"Kristiansen","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.jbo.2024.100635_b0775","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11033-011-0783-5","article-title":"Clinical implications of activated leukocyte cell adhesion molecule expression in breast cancer","volume":"39","author":"Piao","year":"2012","journal-title":"Mol. Biol. Rep."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0780","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/neuonc\/nor202","article-title":"CD166\/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion","volume":"14","author":"Kijima","year":"2012","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.jbo.2024.100635_b0785","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003114","article-title":"Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy","volume":"9","author":"Lin","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.jbo.2024.100635_b0790","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003114","article-title":"Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy","volume":"9","author":"Lin","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0795","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ijc.23587","article-title":"Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy","volume":"123","author":"DaneshManesh","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0800","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","article-title":"Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia","volume":"14","author":"Baskar","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.jbo.2024.100635_b0805","first-page":"2931","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia blood","volume":"128","author":"Cui","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.jbo.2024.100635_b0810","series-title":"Seminars in Cancer Biology","article-title":"The receptor tyrosine kinase ROR1\u2013an oncofetal antigen for targeted cancer therapy","author":"Hojjat-Farsangi","year":"2014"},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0815","doi-asserted-by":"crossref","first-page":"e31127","DOI":"10.1371\/journal.pone.0031127","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0820","doi-asserted-by":"crossref","first-page":"e21018","DOI":"10.1371\/journal.pone.0021018","article-title":"Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.jbo.2024.100635_b0825","first-page":"4532","article-title":"The B-cell tumor\u2013associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b0830","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jbo.2024.100635_b0835","doi-asserted-by":"crossref","first-page":"S896","DOI":"10.1016\/j.annonc.2022.07.903","article-title":"777TiP Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors","volume":"33","author":"Spigel","year":"2022","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.jbo.2024.100635_b0840","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.3390\/cancers14153618","article-title":"Developing ROR1 targeting CAR-T cells against solid tumors in preclinical studies","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jbo.2024.100635_b0845","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"Satelli","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"issue":"19","key":"10.1016\/j.jbo.2024.100635_b0850","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.3390\/cancers13194985","article-title":"Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis","volume":"13","author":"Usman","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0855","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.yexcr.2007.03.040","article-title":"Novel functions of vimentin in cell adhesion, migration, and signaling","volume":"313","author":"Ivaska","year":"2007","journal-title":"Exp. Cell Res."},{"issue":"30","key":"10.1016\/j.jbo.2024.100635_b0860","doi-asserted-by":"crossref","first-page":"49329","DOI":"10.18632\/oncotarget.17632","article-title":"EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression","volume":"8","author":"Satelli","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0865","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.0902371","article-title":"IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors","volume":"184","author":"Zhu","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbo.2024.100635_b0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0631-z","article-title":"Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile","volume":"7","author":"Zhao","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0875","article-title":"Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors","volume":"10","author":"Hu","year":"2022","journal-title":"J, Immunother. Canc."},{"key":"10.1016\/j.jbo.2024.100635_b0880","first-page":"509","article-title":"Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients","author":"Bruland","year":"2010","journal-title":"Pediat. Adolesc. Osteosarc."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0885","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ijc.2910380106","article-title":"New monoclonal antibodies specific for human sarcomas","volume":"38","author":"Bruland","year":"1986","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b0890","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/0959-8049(94)00304-N","article-title":"Immunoscintigraphy of bone sarcomas\u2014results in 5 patients","volume":"30","author":"Bruland","year":"1994","journal-title":"Eur. J. Cancer"},{"issue":"18","key":"10.1016\/j.jbo.2024.100635_b0895","first-page":"5302","article-title":"Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen","volume":"48","author":"Bruland","year":"1988","journal-title":"Cancer Res."},{"issue":"45","key":"10.1016\/j.jbo.2024.100635_b0900","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0278-7","article-title":"New horizons in tumor microenvironment biology: challenges and opportunities","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b0915","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/2159-8290.CD-12-0329","article-title":"The initial hours of metastasis: the importance of cooperative host\u2013tumor cell interactions during hematogenous dissemination","volume":"2","author":"Labelle","year":"2012","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b0920","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","article-title":"Microenvironmental regulation of therapeutic response in cancer","volume":"25","author":"Klemm","year":"2015","journal-title":"Trends Cell Biol."},{"issue":"16","key":"10.1016\/j.jbo.2024.100635_b0925","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0930","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.suronc.2011.09.001","article-title":"The tumor microenvironment","volume":"21","author":"Weber","year":"2012","journal-title":"Surg. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0935","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/cancers12020375","article-title":"Design and characterization of an \u201call-in-one\u201d lentiviral vector system combining constitutive anti-GD2 CAR expression and inducible cytokines","volume":"12","author":"Zimmermann","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0940","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/gt.2017.81","article-title":"Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy","volume":"25","author":"Huang","year":"2018","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0945","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1038\/s41467-021-26352-2","article-title":"Regulatory T cells promote cancer immune-escape through integrin \u03b1v\u03b28-mediated TGF-\u03b2 activation","volume":"12","author":"Lain\u00e9","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0950","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b0955","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/btm2.10097","article-title":"TGF-\u03b2\u2013responsive CAR-T cells promote anti-tumor immune function","volume":"3","author":"Hou","year":"2018","journal-title":"Bioeng. Transl. Med."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b0960","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-20-1243","article-title":"CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies","volume":"11","author":"Wang","year":"2021","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.jbo.2024.100635_b0965","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b0970","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D\u2019Aloia","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b0975","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41413-023-00246-z","article-title":"Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment","volume":"11","author":"Tian","year":"2023","journal-title":"Bone Res."},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b0980","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-17-1365","article-title":"T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2024.100635_b0985","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2018","journal-title":"Molec, Therapy-Oncolyt,"},{"issue":"23","key":"10.1016\/j.jbo.2024.100635_b0990","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbo.2024.100635_b0995","doi-asserted-by":"crossref","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"issue":"50","key":"10.1016\/j.jbo.2024.100635_b1000","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Nat. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b1005","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b1010","doi-asserted-by":"crossref","first-page":"p. nwab172","DOI":"10.1093\/nsr\/nwab172","article-title":"Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy","volume":"9","author":"Li","year":"2022","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.jbo.2024.100635_b1015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1290762","article-title":"Current status and future challenges of CAR-T cell therapy for osteosarcoma","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.jbo.2024.100635_b1020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b1025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b1030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b1035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b1040","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","article-title":"Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion","volume":"21","author":"Yu","year":"2020","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.jbo.2024.100635_b1045","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b1050","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b1055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0628-7","article-title":"PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes","volume":"7","author":"Ogando","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b1060","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.4049\/jimmunol.1402180","article-title":"Programmed death-1 controls T cell survival by regulating oxidative metabolism","volume":"194","author":"Tkachev","year":"2015","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/j.jbo.2024.100635_b1065","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.3390\/cells11223626","article-title":"Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors","volume":"11","author":"Cheever","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b1070","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41577-021-00539-6","article-title":"Cellular networks controlling T cell persistence in adoptive cell therapy","volume":"21","author":"Chan","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b1075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b1080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2024.100635_b1085","first-page":"3","article-title":"Toxicity and management in CAR T-cell therapy","author":"Bonifant","year":"2016","journal-title":"Molec. Therapy-Oncolyt."},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b1090","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/PPO.0000000000000377","article-title":"Management of T-cell engaging immunotherapy complications","volume":"25","author":"Varadarajan","year":"2019","journal-title":"Cancer J."},{"issue":"8","key":"10.1016\/j.jbo.2024.100635_b1095","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b1100","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell\u2013associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b1105","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.jbo.2024.100635_b1110","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b1115","first-page":"697","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"7735","key":"10.1016\/j.jbo.2024.100635_b1120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","article-title":"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome","volume":"564","author":"Staedtke","year":"2018","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.jbo.2024.100635_b1125","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.3390\/cancers13225606","article-title":"A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma","volume":"13","author":"Seefat","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b1130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/13696998.2023.2173466","article-title":"Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed\/refractory multiple myeloma patients in Canada and France","volume":"26","author":"Karampampa","year":"2023","journal-title":"J. Med. Econ."},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b1135","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oncolo\/oyac054","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory follicular lymphoma","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jbo.2024.100635_b1140","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b1145","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/13696998.2023.2207742","article-title":"Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma in China","volume":"26","author":"Wu","year":"2023","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jbo.2024.100635_b1150","doi-asserted-by":"crossref","unstructured":"A.J. Raymakers, Regier, D.A., Peacock, S.J., Modelling Uncertainty in Survival and Cost-Effectiveness is Vital in the Era of Gene Therapies: The Case of Axicabtagene Ciloleucel, Elsevier, 2019. pp. 103\u2013104.","DOI":"10.1016\/j.hlpt.2019.05.009"},{"issue":"7903","key":"10.1016\/j.jbo.2024.100635_b1155","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jbo.2024.100635_b1160","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"25","key":"10.1016\/j.jbo.2024.100635_b1165","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.jbo.2024.100635_b1170","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-Generation CAR T-cell Therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.jbo.2024.100635_b1175","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbo.2024.100635_b1180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687822","article-title":"Obstacles and coping strategies of CAR-T Cell immunotherapy in solid tumors","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b1185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"issue":"17","key":"10.1016\/j.jbo.2024.100635_b1190","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.jbo.2024.100635_b1195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168706","article-title":"TGF-\u03b2\/IL-7 chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma","volume":"22","author":"Noh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"625","key":"10.1016\/j.jbo.2024.100635_b1200","doi-asserted-by":"crossref","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b1205","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b1210","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jbo.2024.100635_b1215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780399","article-title":"Implementing logic gates for safer immunotherapy of cancer","volume":"12","author":"Savanur","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b1220","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"issue":"591","key":"10.1016\/j.jbo.2024.100635_b1225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"6625","key":"10.1016\/j.jbo.2024.100635_b1230","doi-asserted-by":"crossref","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jbo.2024.100635_b1235","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40259-017-0247-0","article-title":"Next-generation chimeric antigen receptor T-cell therapy: going off the shelf","volume":"31","author":"Ruella","year":"2017","journal-title":"BioDrugs"},{"issue":"24","key":"10.1016\/j.jbo.2024.100635_b1240","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jbo.2024.100635_b1245","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201cOff-the-Shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b1250","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/bit.27882","article-title":"Strengthening the CAR-T cell therapeutic application using CRISPR\/Cas9 technology","volume":"118","author":"Sadeqi Nezhad","year":"2021","journal-title":"Biotechnol. Bioeng."},{"issue":"3","key":"10.1016\/j.jbo.2024.100635_b1255","first-page":"311","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"9","key":"10.1016\/j.jbo.2024.100635_b1260","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.jbo.2024.100635_b1265","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbo.2024.100635_b1270","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2020.00888","article-title":"The advent of CAR T-cell therapy for lymphoproliferative neoplasms: integrating research into clinical practice","volume":"11","author":"Cerrano","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbo.2024.100635_b1275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"95","key":"10.1016\/j.jbo.2024.100635_b1280","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"16","key":"10.1016\/j.jbo.2024.100635_b1285","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jbo.2024.100635_b1290","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"Biomarker Res."},{"key":"10.1016\/j.jbo.2024.100635_b1295","doi-asserted-by":"crossref","first-page":"1199145","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.jbo.2024.100635_b1300","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.jbo.2024.100635_b1305","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1172\/JCI65899","article-title":"Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance","volume":"124","author":"Jandus","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jbo.2024.100635_b1310","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.stem.2012.07.014","article-title":"Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types","volume":"11","author":"Taylor","year":"2012","journal-title":"Cell Stem Cell"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424001155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424001155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T16:15:06Z","timestamp":1732810506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137424001155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":262,"alternative-id":["S2212137424001155"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100635","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100635"}}